KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $4.3 billion.

  • Bristol Myers Squibb's Accounts Payables rose 2360.91% to $4.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 billion, marking a year-over-year increase of 2360.91%. This contributed to the annual value of $3.6 billion for FY2024, which is 1052.47% up from last year.
  • As of Q3 2025, Bristol Myers Squibb's Accounts Payables stood at $4.3 billion, which was up 2360.91% from $5.4 billion recorded in Q2 2025.
  • Over the past 5 years, Bristol Myers Squibb's Accounts Payables peaked at $5.4 billion during Q2 2025, and registered a low of $2.6 billion during Q3 2022.
  • Moreover, its 5-year median value for Accounts Payables was $3.2 billion (2023), whereas its average is $3.4 billion.
  • As far as peak fluctuations go, Bristol Myers Squibb's Accounts Payables plummeted by 2014.41% in 2022, and later skyrocketed by 4468.14% in 2025.
  • Bristol Myers Squibb's Accounts Payables (Quarter) stood at $2.9 billion in 2021, then grew by 3.09% to $3.0 billion in 2022, then increased by 7.2% to $3.3 billion in 2023, then increased by 10.52% to $3.6 billion in 2024, then grew by 19.04% to $4.3 billion in 2025.
  • Its last three reported values are $4.3 billion in Q3 2025, $5.4 billion for Q2 2025, and $4.0 billion during Q1 2025.